FDA Extends Review for Denali's Hunter Syndrome Breakthrough: A Closer Look at Tividenofusp Alfa's Path to Approval
Amneal Pharmaceuticals Eyes Major Market Entry with Xolair Biosimilar, Pledging Affordable Relief
Brainstorm Cell Therapeutics Unveils Robust Q2 2025 Financials and Pivotal Clinical Advancements